November 28, 2024

CRC 1249 – Funding for Collaborative Research Centre in Chemistry

CRC 1249 – Funding for Collaborative Research Centre in Chemistry

The German Research Foundation providing funding of around 10,9 million euros

With a Collaborative Research Centre in chemistry, Heidelberg University has been successful in the latest approval round of the German Research Foundation (DFG). The CRC 1249 “N-Heteropolycycles as Functional Materials”, where research is being carried out on novel organic compounds, is entering its third funding period. The DFG is providing funding of around 10,9 million euros for the research consortium over a period of four years. Prof. Dr Petra Tegeder from the Institute for Physical Chemistry at Ruperto Carola will serve as spokesperson.

Petra Tegeder
Petra Tegeder | © private

The focus of CRC 1249 is the development of novel organic functional materials with specifically tunable electronic and optical properties and their application as photoactive components and organic semiconductors. This is done on the basis of a large and flexibly variable class of organic hydrocarbon compounds with ring structures containing nitrogen atoms. The research plan comprises the development of synthetic-chemical methods, structural and spectroscopic characterization as well as the theoretical modeling of molecules, aggregates and solid films. Of particular interest is the way in which molecular properties are related to the optoelectronic properties of materials and devices.

The Collaborative Research Centre is supported by researchers from the three Institutes of Chemistry, the Interdisciplinary Center for Scientific Computing and the Institute for Molecular Systems Engineering and Advanced Materials at Heidelberg University. Research groups from the Karlsruhe Institute of Technology and the Max Planck Institute for Solid State Research in Stuttgart are also participating. The CRC 1249 will reach the maximum funding period of twelve years.

Further information

Participating Institutions

Our latest News

discover more
New bioRN Members of 2025

New bioRN Members of 2025

In 2025, the bioRN cluster experienced a strong and dynamic expansion as many new members joined its growing network. This influx of new companies and institutions further strengthened the cluster’s expertise, diversity, and innovative power. The cluster is now pleased to introduce these new members and highlight the diverse capabilities they bring, further reinforcing its […]

ariadne.ai Secures Invest BW Funding to Build “TumorTwin”: The First Digital Twin for Glioblastoma Powered by Morphometric Spatial Multi-Omics

ariadne.ai Secures Invest BW Funding to Build “TumorTwin”: The First Digital Twin for Glioblastoma Powered by Morphometric Spatial Multi-Omics

HEIDELBERG, Germany – January 9, 2026 – ariadne.ai (Germany) GmbH today announced it has been awarded €518,000 in non-dilutive funding from the State of Baden- Württemberg (Invest BW) for its ambitious new project, TumorTwin. The project aims to revolutionize the treatment of Glioblastoma, one of the deadliest and most aggressive brain tumors, by creating a […]

AMGEN acquires Dark Blue Therapeutics, bolstering oncology pipeline

AMGEN acquires Dark Blue Therapeutics, bolstering oncology pipeline

Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million.   The acquisition adds to Amgen’s […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp